Business Context and Reporting Period
Ambarella, Inc. filed this Form 8-K on February 26, 2021, to disclose executive compensation decisions approved by the Board of Directors. The filing covers the approval of the Fiscal Year 2022 Annual Bonus Plan, the payout of the Fiscal Year 2021 Annual Bonus Plan, and base salary adjustments effective February 1, 2021.
Key Financial Metrics and Compensation Details
- FY2021 Bonus Payout: The executive bonus pool was funded at 113.6% of target after a portion was reallocated to non-executive employees. Performance exceeded targets for operating profit and non-financial objectives but fell slightly short on revenue.
- Named Executive Officer (NEO) Awards:
- Feng-Ming Wang: $500,000
- Leslie Kohn: $250,000
- Casey Eichler: $188,000
- Michael Chen: $92,880
- Christopher Day: $90,000
- Payment Method: Awards are paid in fully-vested stock awards in March 2021, subject to continued employment.
- FY2022 Bonus Plan: The aggregate target bonus pool is approximately 22% larger than the FY2021 plan. Performance metrics are weighted equally (1/3 revenue, 1/3 operating profit, 1/3 non-financial objectives). Maximum payout is 150% of target.
- Base Salary Increases: Dr. Wang's salary increased by 45% to $550,000. Other NEOs received a 3.3% increase.
Material Changes Versus Prior Period
The primary material change is the 22% increase in the aggregate target bonus pool for FY2022 compared to FY2021. Additionally, the FY2021 payout structure saw a strategic reallocation where funds originally calculated for executives (129% of target) were reduced to 113.6% of target to fund bonuses for non-executive employees.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, revenue forecasts, or liquidity metrics. The Compensation Committee retains discretion to adjust the bonus pool size and individual payouts based on corporate goals. Payouts are contingent upon continued employment through the payment date.
Investor Verification Checklist
- Verify the total number of shares issued for the FY2021 stock-based bonus awards in the March 2021 payment cycle.
- Confirm the specific non-financial operational objectives used to calculate the 1/3 performance weighting.
- Review the impact of the 45% salary increase for Dr. Wang on total executive compensation expense for FY2022.
- Check subsequent filings for the actual FY2022 performance results against the new revenue and operating profit targets.